A61P17/00

Personal Care Compositions Incorporating Natural Benefit Agents and Methods for the Same

Solid cleansing compositions and methods for the same are disclosed herein. The solid cleansing composition may include a soap and a plant oil. The plant oil may include flaxseed oil, and may be present in an amount effective to maintain or increase hydration of skin, inhibit inflammation of skin, deodorize skin, inhibit irritation of skin, or combinations thereof.

COMPOSITIONS COMPRISING EXTRACELLULAR VESICLES, SECRETED BIOMOLECULES, AND/OR CONDITIONED MEDIA, AND METHODS OF PRODUCING AND USING THE SAME
20230043556 · 2023-02-09 ·

The disclosure relates to novel compositions comprising 1) conditioned media, 2) combinations of secreted biomolecules/organic molecules, and/or 3) secreted extracellular vesicles/exosomes collected from differentiated epithelial cell culture, as well as methods of making and using such compositions.

SKIN SOOTHING COMPOSITION INCLUDING EXOSOMES DERIVED FROM NATURAL EXTRACT
20230042326 · 2023-02-09 · ·

Disclosed is a cosmetic composition for skin soothing. The cosmetic composition includes, as active ingredients, exosomes derived from naturally occurring deer antler velvet. The cosmetic composition can effectively soothe the skin whose condition has been abnormally altered (such as atopic dermatitis, inflammation, erythema, oxidation, cytotoxic agents in the skin, loss of moisture, melasma, itching, roughness or wrinkles) by various causes.

SKIN SOOTHING COMPOSITION INCLUDING EXOSOMES DERIVED FROM NATURAL EXTRACT
20230042326 · 2023-02-09 · ·

Disclosed is a cosmetic composition for skin soothing. The cosmetic composition includes, as active ingredients, exosomes derived from naturally occurring deer antler velvet. The cosmetic composition can effectively soothe the skin whose condition has been abnormally altered (such as atopic dermatitis, inflammation, erythema, oxidation, cytotoxic agents in the skin, loss of moisture, melasma, itching, roughness or wrinkles) by various causes.

Purine diones as Wnt pathway modulators

The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

CONTROL OF HISTAMINE TO PROMOTE HEALTH AND CONTROL ENTEROCOLITIS USING PROBIOTIC COMPOSITIONS AND/OR HISTAMINE DEGRADING ENZYMES
20230011355 · 2023-01-12 ·

The present invention relates to use of probiotic compositions and/or histamine degrading enzymes for the control of histamine in a farm production animal, companion animal, aquaculture, or a human, to reduce or eliminate the incidence of necrotizing enterocolitis and/or related inflammatory conditions in the gastrointestinal tract or skin, and behavioral conditions. The invention also relates to the probiotic compositions and/or histamine degrading enzymes.

METHOD FOR FREEZING AND STORING NEONATAL STROMAL CELLS
20230008313 · 2023-01-12 ·

The present invention relates to a method for freezing and preserving a composition comprising a population of neonatal stromal cells (NSCs) and a cryoprotector, characterised in that it comprises a step of freezing the composition at a temperature of between −70° C. and −140° C., then a step of preserving the composition at between −10° C. and −40° C. The present invention also relates to a composition comprising a population of NSCs and a cryoprotector, characterised in that it is preserved at between −10° C. and −40° C., said NSCs being in particular placental NSCs.

IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF
20230008368 · 2023-01-12 ·

The present invention relates to an imidazoquinoline substituted phosphoric ester agonist, and a preparation therefor and an application thereof. Specifically, the compounds of the present invention have the structure shown in formula (I), wherein the definition of each group and substituent is as described in the description. Also disclosed in the present invention are a preparation method for the compound and use thereof as a TLR agonist.

##STR00001##

MIXTURE OF HMOS FOR IMPROVING THE MICROBIOTA OF PREGNANT WOMEN

The invention relates to a human milk oligosaccharide (HMO) for use in supplementing the diet of a pregnant woman, a synthetic composition comprising an HMO for use in supplementing the diet of a pregnant woman, and a method for improving health outcomes in an infant by supplementing the diet of a pregnant woman.